Oric Pharmaceuticals (ORIC) AI Stock Analysis

• Market Cap: $1.19B
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: N/A
• EPS Growth: 4.29%
• Country: US
• Employees: 122
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 100,358,240
• 10 Day Avg. Volume: 1,737,368
• 30 Day Avg. Volume: 1,539,504
• PEG Ratio: 0.28
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.30
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.73K
• Enterprise Value/Ebitda: -8.92
• 1Y Price Target: $20.30
• Price Target Upside: 66.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.41
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $12.00 ▼(-1.80% Downside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is primarily supported by a strong, low-leverage balance sheet and reasonable liquidity, but is held back by the lack of revenue, sizable ongoing losses, and sustained cash burn. Technicals are moderately supportive (longer-term averages and MACD), while valuation metrics are challenged by negative earnings and no dividend yield.

Positive Factors

Balance sheet strength

Low leverage and a meaningful asset build provide durable funding flexibility for multi-year clinical development. Reduced refinancing pressure and positive equity improve the company’s ability to support R&D and absorb trial timing variability, strengthening execution capacity over the next several quarters.

Focused oncology pipeline

A clear strategic focus on small-molecule programs targeting treatment resistance addresses a persistent unmet need in oncology. This specialization can yield durable competitive differentiation and high-value endpoints if clinical proof-of-concept is achieved, aligning with long-term industry demand for resistance solutions.

Access to public equity financing (ATM)

An active ATM program and recent large issuances give structural access to capital markets, extending runway and enabling staged financing of clinical programs. Reliable equity access reduces short-term funding uncertainty and allows management to time raises to program milestones rather than urgent liquidity needs.

Negative Factors

No revenue / pre-revenue

As a pre-revenue clinical-stage company, ORIC lacks internal product cash generation, meaning long lead times to commercial sales. This structurally increases reliance on external capital and creates binary outcome risk tied to clinical and regulatory success, which can materially affect long-term viability.

Sustained cash burn

Consistent negative operating and free cash flow implies ongoing funding needs and rising consumption of resources. Persistent burn constrains optionality, may force program prioritization or delays, and can erode the current asset cushion if clinical timelines extend or costs increase.

Reliance on financing activity

Dependence on market financing exposes operations to investor sentiment and market conditions. Repeated capital raises risk dilution, could compel suboptimal partnering or licensing terms, and elevates execution risk if access to public/private funding tightens during critical development phases.

Oric Pharmaceuticals Business Overview & Revenue Model

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

How the Company Makes Money

ORIC does not have publicly established recurring revenue from approved commercial products; as a clinical-stage company, its operations have historically been funded primarily through financing activities rather than product sales. Where applicable, ORIC may generate limited revenue via collaborations or licensing arrangements (e.g., upfront payments, research funding reimbursements, and milestone-based payments tied to development, regulatory, or commercialization events), and potentially future royalties on partner sales if any partnered products reach market. Specific current partners, deal terms, and the materiality of collaboration revenue to ORIC’s results are null.

Oric Pharmaceuticals Financial Statement Overview

Summary

Balance sheet strength (minimal debt, positive equity, and higher total assets in 2025) supports funding flexibility, but this is offset by no revenue, widening net losses, and persistently negative operating/free cash flow indicating ongoing funding needs.

Income Statement

The income statement remains weak, with no reported revenue across the period and consistently large operating losses. Losses have generally widened versus earlier years (net loss roughly -$74M in 2020 to about -$129M in 2025), indicating a higher spend profile. A modest positive is that results appear relatively consistent year-to-year for a development-stage biotech, but the absence of revenue and persistent negative profitability are the primary constraints.

Balance Sheet

The balance sheet is a clear strength: the company operates with minimal to no debt (debt-to-equity near zero in most years) and maintains positive equity. Total assets increased meaningfully into 2025 (about $409M vs. ~$274M in 2024), supporting liquidity and funding capacity. The key weakness is ongoing negative returns on equity in prior years (driven by net losses), which can pressure the capital base over time if losses persist.

Cash Flow

Cash flow is pressured by sustained cash burn: operating cash flow and free cash flow are negative every year shown (around -$111M in 2025). Free cash flow deterioration in 2025 versus 2024 suggests burn may be rising rather than stabilizing. A relative positive is that free cash flow broadly tracks net loss (cash usage roughly in line with accounting losses), but the overall profile still indicates ongoing funding needs until revenue ramps.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.22M	-1.11M	-1.03M	0.00	0.00
EBITDA	-128.25M	-126.74M	-109.75M	-85.80M	-77.97M
Net Income	-129.47M	-127.85M	-100.70M	-89.12M	-78.72M
Balance Sheet
Total Assets	411.00M	274.14M	254.69M	250.36M	298.64M
Cash, Cash Equivalents and Short-Term Investments	281.49M	255.96M	208.19M	206.27M	236.98M
Total Debt	11.55M	3.18M	10.21M	12.10M	1.93M
Total Liabilities	26.64M	31.02M	30.60M	28.01M	25.67M
Stockholders Equity	384.36M	243.12M	224.09M	222.35M	272.98M
Cash Flow
Free Cash Flow	-114.08M	-113.85M	-86.54M	-77.22M	-60.48M
Operating Cash Flow	-113.37M	-112.66M	-85.69M	-75.14M	-59.54M
Investing Cash Flow	-148.03M	22.14M	-43.40M	-109.25M	158.44M
Financing Cash Flow	245.26M	126.55M	85.66M	25.23M	49.13M

Oric Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Neutral. The current price of 12.22 is below the 20-day moving average (MA) of 12.50, above the 50-day MA of 11.28, and above the 200-day MA of 10.91, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 50.96 is Neutral, neither overbought nor oversold. The STOCH value of 31.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORIC.

Oric Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	67 Neutral	$8.49B	-21.87	-58.74%	―	364.98%	-25.33%
SYRE	59 Neutral	$3.46B	-45.32	-29.44%	―	―	-123.65%
ORIC	57 Neutral	$1.19B	―	-38.79%	―	―	4.29%
TRVI	57 Neutral	$1.43B	-28.12	-31.23%	―	―	15.84%
PHAR	57 Neutral	$1.09B	440.65	0.87%	―	26.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRME	50 Neutral	$662.63M	-2.57	-178.61%	―	647.13%	26.79%

Oric Pharmaceuticals Corporate Events

Oric Pharmaceuticals Launches New 2026 ATM Share Program

On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell common shares through an at-the-market offering program, using Jefferies as sales agent under an effective shelf registration filed on March 11, 2024. Under a 2024 prospectus supplement tied to this agreement, the company sold 13,478,432 shares for gross proceeds of about $139.7 million as of February 23, 2026, and on February 26, 2026, it transitioned to a new 2026 prospectus supplement for up to $200 million in additional share sales, with no further issuances to occur under the 2024 supplement.

The most recent analyst rating on (ORIC) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.